This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Torasemide oral

Updated 2 Feb 2023 | Loop diuretics


Oral formulations of torasemide.

Drugs List

  • torasemide 10mg tablets
  • torasemide 2.5mg tablets
  • torasemide 5mg tablets
  • TOREM 10mg tablets
  • TOREM 2.5mg tablets
  • Therapeutic Indications


    Oedema due to cardiac failure
    Oedema of hepatic/pulmonary or renal origin
    Treatment of essential hypertension



    Essential hypertension:
    The recommended dose is 2.5mg once daily, increased if necessary to 5mg once daily. Studies suggest that doses above 5mg daily will not lead to further reduction in blood pressure. The maximum effect is exhibited after approximately twelve weeks of continuous treatment.

    The usual dose is 5mg once daily. If necessary, the dose can be increased stepwise up to 20mg once daily. In individual cases, as much as 40mg torasemide per day has been administered.


    Children under 18 years
    Cardiac arrhythmias
    Hepatic coma
    Long QT syndrome
    Pre-coma associated with hepatic cirrhosis
    Renal damage secondary to nephrotoxic agents
    Renal impairment secondary to hepatotoxic agents
    Severe hypokalaemia
    Severe hyponatraemia
    Torsade de pointes

    Precautions and Warnings

    Family history of long QT syndrome
    Benign prostatic hyperplasia
    Diabetes mellitus
    Electrolyte imbalance
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    History of torsade de pointes
    Lactose intolerance
    Urinary obstruction

    Correct hypotension before initiating treatment
    Advise ability to drive/operate machinery may be affected by side effects
    Correct existing water and electrolyte disturbances before administration
    Not all available strengths are licensed for all indications
    Contains lactose
    Monitor serum electrolytes before and during treatment
    Consider monitoring ECG in patients at risk of QT prolongation
    Monitor antidiabetic drug treatment
    Monitor blood / urinary glucose in patients suspected of latent diabetes
    Monitor blood glucose
    Monitor carbohydrate metabolism in diabetes mellitus
    Monitor patients at risk of gout
    Monitor renal function
    Monitor serum creatinine
    Monitor serum lipids
    Monitor uric acid levels
    Excess consumption of liquorice may increase the risk of hypokalaemia
    Advise patient not to take NSAIDs unless advised by clinician

    Use with caution in patients with urinary outflow obstruction such as in prostatic enlargement as torasemide may precipitate urinary retention in these patients.

    Pregnancy and Lactation


    Torasemide is contraindicated in pregnancy.

    Diuretics are no longer part of the standard therapy for hypertension and oedema during pregnancy, they should only be used for particular indications. There are no data available on the effect of torasemide on the human embryo and foetus. Whilst studies in rats have shown no teratogenic effect, malformed foetuses have been observed after high doses in pregnant rabbits.

    Schaefer (2007) concludes that use of torasemide is not an indication for termination of pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Torasemide is contraindicated during breastfeeding.

    No studies have been conducted on excretion in breast milk. Its extraordinary high protein binding is likely to limit its transfer into human milk. As with many diuretics, reduction of plasma volume and hypotension may adversely reduce milk production. An alternative agent may be preferred especially whilst nursing a newborn or premature infant. Schaefer (2007) states that single doses of torasemide do not require limitation of breastfeeding, but therapy should be changed.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Aggravation of metabolic alkalosis
    Allergic reaction
    Bladder outflow obstruction
    Cerebral ischaemia
    Circulatory disturbances
    Decreased appetite
    Disturbance of fluid balance
    Dry mouth
    Electrolyte disturbances
    Gastro-intestinal symptoms
    Hearing loss
    Increase in serum glucose
    Increased uric acid level
    Increases in hepatic enzymes
    Muscular cramps
    Myocardial infarction
    Myocardial ischaemia
    Rise in blood lipids
    Serum creatinine increased
    Serum urea increased
    Stevens-Johnson syndrome
    Thromboembolic complications
    Toxic epidermal necrolysis
    Urinary retention
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2017.

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Torem tablets 2.5mg. Meda Pharmaceuticals Ltd. Revised July 2016.
    Summary of Product Characteristics: Torem tablets 5mg. Meda Pharmaceuticals Ltd. Revised July 2016.
    Summary of Product Characteristics: Torem tablets 10mg. Meda Pharmaceuticals Ltd. Revised July 2016.

    The Norwegian Porphyria Centre (NAPOS).
    Available at:
    Last revised: 16 April 2010.
    Last accessed: 04 December 2017.

    NICE Evidence Services Available at: Last accessed: 04 December 2017.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Torasemide. Last revised: 10 March 2015.
    Last accessed: 04 December 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.